Topic Listing for Arena Pharmaceuticals

Access Resources Account
Accounting Lease Financing Obligations Accounts Payable Accrued Compensation Other Liabilities
Accounts Payable Accrued Expenses Accretion Discount Deemed Dividend Redeemable Convertible Preferred Stock
Accretion Discount Redeemable Convertible Preferred Stock Accretion Discount Related Redeemable Convertible Preferred Stock
Acknowledgement Term Commencement Date Expiration Acquired Technology Other Intangibles
Actual Minimum Additional Bloom Data
Additional Blossom Data Adea
Adjustment Change Capitalization Adjustment Price
Adjustments Adjustments Certain Events
Adjustments Changes Capitalization Adjustments Changes Capitalization Dissolution Liquidation Merger Asset Sale
Administration Adoption New Accounting Standards
Advance Lead Programs Agent Service Legal Process
Aggregated Option Exercises Last End Values Agreement
Agreement Loan Agreement Not Contract
Agreement Purchase Sale 6114 6118 6122 6124 6126 Agreement Shall Governed Construed Accordance Laws State New
Aivers Ights Hereunder Umulative Alternate Consideration
Amendment Amendment Registration Rights Agreement
Amendment Research Collaboration License Agreement Amendment Termination
Amendment Termination 2006 Ltip Amendment Termination Plan
Amendments Agreement Amendments Articles Incorporation Bylaws Change
Amortization Acquired Technology Amortization Deferred Compensation
Amount Benefit Annex
Annual Audit Related Disclosure Annual Incentive Plan
Annual Performance Evaluations Assessment Charters Annual Report
Annual Report Form 10-k Apd125
Apd125-001 Apd125-002
Apd125-003 Apd356
Apd668 Ortho-mcneil Collaboration Apd791
Appendix Appendix Computation Examples
Appendix Example Manufacturing Plan Appendix Example Product Forecast
Appendix Maximum Quantities Products Appendix Product Specifications
Appendix Products Appendix Quality Agreement
Appendix Standard Cost Applications Benefits Inquiries
Appraiser Appreciation Right Dividend Equivalents Make Other Determination Take
Approval 2001 Arena Employee Stock Purchase Plan Amended Approval 2009 Employee Stock Purchase Plan
Approval 2009 Long-term Incentive Plan Approval Amendment Fifth Amended Restated Certificate Incorporation
Approval Amendment Fifth Amended Restated Certificate Incorporation Increase Approval Arena Pharmaceuticals Inc 2006 Long-term Incentive Plan
Approval Arena Pharmaceuticals Inc 2009 Employee Stock Purchase Approval Arena Pharmaceuticals Inc 2009 Long-term Incentive Plan
Arbitration Arena Employee Stock Purchase Plan
Arena Indemnitee Arena Patent Prosecution
Arena Pharmaceuticals Arena Pharmaceuticals Announces 2005 Financial Results
Arena Pharmaceuticals Announces 2006 Financial Results Arena Pharmaceuticals Announces 2007 Financial Results
Arena Pharmaceuticals Announces 2008 Financial Results Arena Pharmaceuticals Announces 2008 Financial Results Recent Highlights
Arena Pharmaceuticals Announces 2009 Financial Results Arena Pharmaceuticals Announces 2009 Financial Results Recent Developments
Arena Pharmaceuticals Announces Exercise Over-allotment Option Underwriters Arena Pharmaceuticals Announces Full 2004 Financial Results
Arena Pharmaceuticals Announces Full 2006 Financial Results Arena Pharmaceuticals Announces Full 2007 Financial Results
Arena Pharmaceuticals Announces Full 2008 Financial Results Arena Pharmaceuticals Announces Pricing Public Offering Common Stock
Arena Pharmaceuticals Inc Arena Pharmaceuticals Inc 2006 Long-term Incentive Plan
Arena Pharmaceuticals Inc 6150 Nancy Ridge Drive San Arena Pharmaceuticals Inc 6166 Nancy Ridge Drive San
Arena Pharmaceuticals Inc Index Financial Statements Arenas 2005 Highlights
Arenas 2006 Highlights Arenas 2006 Highlights Date
Arenas 2007 Highlights Arenas 2007 Highlights Date
Arenas 2008 Highlights Date Arenas Highlights
Arenas Recent Developments Arenas Recent Highlights
Asset Acquisition Siegfried Ltd Related Agreements Assistance Questions
Audit Committee Audit Committee Report
Audit Fees Audit-related Fees
Auditor Independence Auditor Letters
Auditor Reports Auditors
Authority Authorized Signatures-this Completed Vote Counted-date Sign Below
Available Information Available-for-sale Securities
Award Award Agreement
Award Agreements Base Salary
Basic Annual Rent Increase Basic Annual Rent Reduction
Basis Payments Plan Basis Presentation
Bear Cost Soliciting Votes Meeting Beneficial Owner Shares Registered Name Bank Broker Other
Beneficial Ownership Reporting Compliance Beneficiary
Best Interests Respect Criminal Proceeding Indemnitee Had Reasonable Biocom Investor Conference 31-november San Diego California
Biological Materials Hazardous Chemicals Radioactive Compounds Black-scholes Value
Bloom Trial Design Blossom Confirms Bloom
Blossom Trial Design Bmr-6114-6154 Nancy Ridge Drive Llc
Board Board Directors Stockholders Arena Pharmaceuticals Inc
Board Standing Committees Body Composition
Bona Fide Bonus Amount
Building Closing Conditions Business Experience Directors
Buy-in Buy-in Price
Calculations Calendar
Cannot Protect Intellectual Property Rights Throughout World Cardiovascular
Cardiovascular Risk Factors Cardiovascular Safety
Cart Cash
Cash Amount Cash Bonuses Salary Increases
Cash Compensation Cash Equivalents
Cash Severance Benefits Cause
Certain Adjustments Certain Definitions
Certain Limits Shares Subject Awards Certain Reductions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certification Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Chairperson Change Control
Change Control Corporate Transaction Change Control Provisions
Change Vote After Submitting Proxy Changes Internal Control Over Financial Reporting
Charges Taxes Expenses Chemnavigator
Chief Executive Officer Compensation Clinical Development
Clinical Development Programs Clinical Trial Expenses
Clinical Trials Drug Candidates Expensive Time Consuming Progress Clinical Trials Drug Candidates Expensive Time Consuming Uncertain
Clinical Trials Product Candidates Expensive Time Consuming Interrupted Clinical Trials Product Candidates Expensive Time Consuming Outcome
Clinical Update Lorcaserin Program Closing Certificate
Closing Deliveries Closing Secured Loan
Cns Disorders Cobra
Cobra Benefits Cobra Continuation
Code 162 Performance Goals Code 162 Provisions
Code Business Conduct Ethics Code Conduct Compliance Laws Regulations
Code Ethics Collaboration Agreements Merck Ortho-mcneil Terminated Certain Circumstances
Collaboration License Agreement Collaborative Relationships Lead Delays Drug Development Commercialization Disputes
Collaborative Relationships Lead Disputes Delays Drug Development Commercialization Commitments
Committee Committee Discussions Others
Committee Report Common Shares Reserved Future Issuance
Communications Conflicts Between Auditors Compared 2005
Compared 2006 Compared 2007
Comparison Cumulative Return Investment Compensation Attributable Performance Awards
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Competition Complaint Policy
Completion Acquisition Disposition Assets Compliance Certificate
Compliance Environmental Regulations Compound Patent
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Concentration Credit Risk Major Customers
Conclusion Regarding Effectiveness Disclosure Controls Procedures Condensed Consolidated Balance Sheet Data
Conditions Disbursement Loan Conditions Issuance Shares
Conditions Precedent Confidential Information
Confidential Treatment Been Requested Portions Marked Asterisks Confidential Treatment Requested
Conflicts Collaborators Delay Prevent Development Commercialization Product Candidates Conflicts Prospective Current Past Collaborators Delay Prevent Development
Consent Independent Registered Public Accounting Firm Consolidation Setbacks Industry Collaborators Inability Obtain Acceptable Prices
Continue Advance Lead Programs Continue Build Development Capabilities
Continuing Disagreement Warrant Holders Contractual Obligations Table
Controls Procedures Corp Individual Goals
Corporate Collaborations Corporate Governance Committee
Corporate Governance Guidelines Corporate Governance Nominating Committee
Corporate Governance Nominating Strategy Committee Corporate Individual Goals
Correspondence Regarding Financial Statements Accounting Policies Cost Contract Manufacturing
Cost Manufacturing Services Covenants
Covered Employees Covered Termination
Covered Termination Benefits Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Management Estimates Currency Fluctuations Negatively Affect Financial Condition
Current Global Economic Environment Poses Severe Challenges Business Current Report
Data Phase Obesity Trial Around End Date Issuance Term
Decision Review Deemed Number
Default Remedies Deferral Dividend Equivalents
Deferred Compensation Deferred Rent
Definitions Definitions General Terms
Delegation Subcommittees Delivery
Delivery Warrants Denial Claims
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Derivative Liabilities Description 2009 Espp
Description Capital Stock Description Employee Purchase Plan
Designation Beneficiary Development Lorcaserin Adversely Impacted Cardiovascular Side Effects Previously
Development Partnership Status Development Plan
Development Plans Partnership Status Development Programs Drug Candidates Expensive Time Consuming Uncertain
Development Report Diligence Disputes Remedies
Diligent Efforts Director
Director Compensation Director Compensation Table 2007
Director Election Director Independence
Director Meeting Attendance Director Officer
Directors Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disability
Disagreements Holders Series Preferred Warrants Future Disagreements Warrant Holders
Discover Develop Additional Small Molecule Drug Candidates Targeting Discover Develop Additional Small Molecule Product Candidates Targeting
Discretionary Adjustment Dispute Regarding Infringement Misappropriation Proprietary Rights Others Costly
Dissolution Liquidation Distributed Property
Dividends Dividends Dividend Equivalents
Dividends Redeemable Convertible Preferred Stock Documents Incorporated Reference
Drug Candidates Subject Extensive Regulation Costly Time Consuming Drug Candidates Subject Extensive Regulation Not Receive Required
Drug Discovery Development Intensely Competitive Therapeutic Areas Focus Earlier-stage Development Research Programs
Early Development Election Earnings Press Releases Guidance
Echocardiogram Assessment Effect New Accounting Standards
Effective Date Efforts Seriously Jeopardized Unable Retain Attract Key Employees
Election Directors Eli Lilly
Eligibility Eligibility Administration
Eligibility Awards Granted Certain Individuals Groups Eligibility Benefits
Emedies Employee
Employee Benefit Plan Employee Stock Purchase Plan
Employees Employer Plan Identification Numbers
Employment Contracts Termination Change-in-control Arrangements Encounter Significant Delays Problems Chemical Development Facility
Encounter Significant Delays Problems New Chemical Development Facility Ending Date Plans
Eneral Enforce Rights
Enforcement Engage New Partnerships Other Strategic Transactions Impact Liquidity
Engage Strategic Transactions Impact Liquidity Increase Expenses Present Engagement Auditors Preapproval
Entire Agreement Modification Entry Material Definitive Agreement
Epresentations Arranties Obligor Hereby Represents Warrants Secured Party Equity
Equity Compensation Plans Equity Financing
Erisa Ertain Eleases Ermination
Espp Estimates
Evaluation Auditors Evaluation Disclosure Controls Procedures
Even Drug Candidates Receives Regulatory Approval Still Subject Even Product Candidates Receives Regulatory Approval Still Subject
Even Receive Regulatory Approval Commercialize Drug Candidates Ability Even Receive Regulatory Approval Market Drug Candidates Ability
Events Failure Exact Name Registrant Specified Charter
Except Exchange Act
Exchange Agreement Exclusive Discretion
Execution Execution Copy
Execution Documents Timing Deliveries Conditions Executive
Executive Compensation Executive Officer Compensation Philosophy Objectives Development
Executive Officers Executive Officers Other Directors
Exercise Exercise Date
Exercise Notice Exercise Option
Exercise Options Exercise Price
Exhaustion Remedies Exhibits
Existing Liens Expect Announce Results Most Advanced Product Candidates 2005
Expect Announce Results Most Advanced Product Candidates Middle Expiration Date Stock Appreciation Right Granted Become Exercisable
Explanatory Face Litigation Other Adverse Actions Result Recent Public
Facility Agreement Fair Market Value
Fair Value Disclosures Fair Value Financial Instruments
Fda Draft Guidance Federal Income Tax Consequences
Federal Tax Information Employee Purchase Plan Field Infringement
Final Form Warrant Financial Guidance
Financial Reporting Controls Financial Statement Preparation
Financial Statement Schedules Financial Statements Exhibits
Floating Price Security Focus Attractive Market Opportunities
Focusing Activities Resources Development Lorcaserin Depend Success Following Presents Aggregate Fees Billed 2008 2007 Ernst
Foreign Currency Translation Form 10-k
Form 10-q Form Estoppel Certificate
Form Exercise Notice Form Fixed Request Notice
Form Notice Exercise Purchase Option Form Optional Amount Notice
Former Name Address Changed Since Last Report Forward-looking Statements
Fractional Interests Fractional Shares
Full 2005 Financial Results Fundamental Transaction
Fundamental Transactions Funding Relationship
Funds Future Equity Debt Issuances Dilutive Adverse Effects Existing
General General Administrative Expenses
General Executive Officer Compensation Policy Implementation General Release Not Extend Claims Creditor Know Suspect
Generally Applicable Provisions Governing Law
Governing Law Venue Waiver Jury Trial Government Regulation
Gpcr Technologies Programs Grant Agreement
Grant Option Grant Restricted Stock Units
Grants Headings
Hereas Hiring Policy
Holder Holders
Holders Series Convertible Preferred Stock Entitled Require Redeem Holders Series Preferred Entitled Require Redeem
Holders Series Preferred Require Redeem Holders Stock Other Securities Take Actions Contrary Interests
Householding Proxy Materials Impact Adoption Sfas 123r
Implied Employment Contract Incentive Stock Options
Including Income Taxes
Incur Increased Costs Result Recently Enacted Changes Laws Incur Substantial Liabilities Product Liability Claims Insurance Coverage
Indebtedness Participants Indemnification
Indemnification Agreement Indemnitee
Indemnity Independent Auditors Fees
Index Index Exhibits
Index Financial Statements Inflammatory Disorders
Information Board Directors Committees Information Concerning Solicitation Voting
Information Relating Forward-looking Statements Inspection
Intangible Assets Intangibles
Intellectual Property Intellectual Property Update
Intent-to-treat Last Observation Carried Forward Itt-locf Results Interest
Interest Income Expense Other Net Interest Income Other Net
Interest Other Income Expense Net Interest Other Income Net
Interest Shall Accrue Payroll Deductions Participant Plan Stock Internal Control Integrated Framework
Internal Revenue Code 162 Internet
Interpretation Introduction
Investigations Investment Axiom Biotechnologies Inc Subsequent Acquisition Sequenom
Investment Chemnavigator Investment Policy
Investment Write-down Issuable Maximum
Joint Research Committee Joint Steering Committee
Joint Steering Committee Jsc Jsc
Key Definitions Land Property Equipment
Largest Stockholders Take Actions Contrary Interests Including Selling Latest
Laws Regulations Relating Public Companies Costly Impact Ability Laws Rules Regulations Relating Public Companies Costly Impact
Lease Leases
Legal Construction Legends
Letter Credit Life Disability Coverage
Limitation Exercise Limitation Liability Except Breach
Limitations Grants Individual Participants Liquidity Capital Resources
Litigation Long Term
Long-lived Assets Long-term Incentive Plan
Long-term Incentive Plan Amended Lorcaserin
Lorcaserin Once Daily Lorcaserin Phase Clinical Trial Weight Loss Dose Time
Lorcaserin Twice Daily Losses
Ltip Mail
Maintain Strong Discovery Research Capabilities Maintain Strong Research Discovery Capabilities
Managements Discussion Analysis Managements Report Internal Control Over Financial Reporting
Mandatory Prepayment Manufacturing Sources Availability Raw Materials Intermediates Clinical Supplies
Market Information Marketing Report
Materials Maximum Percentage
Mechanism Action Mechanism Preclinical Data
Meetings Melanophore Technology
Merck Cardiovascular Collaboration Merck Collaboration
Merck Inc Merck Internal Program Information
Merck Know-how Merger Asset Sale
Minimum Vesting Period Miscellaneous
Mitigation Morgan Stanley Global Healthcare Unplugged Conference
Mutates Mutandis Name Person Filing Proxy Statement Other Registrant
Nancy Ridge Drive San Diego California 92121 Nasdaq
Need Additional Funds Conduct Planned Research Development Efforts Net Loss Per Share
New Accounting Guidance New Accounting Pronouncements Impact Future Results Operations
New Accounting Standards New Warrant
Nominating Committee Nominees
Nominees Election Process Non-duplication Benefits
Non-employee Director Non-employee Director Compensation
Non-employee Director Meetings Non-exclusivity Survival Rights Insurance Subrogation
Non-management Director Meetings Non-voting
Noncircumvention Nonqualified Deferred Compensation Table 2007
Nonqualified Deferred Compensation Table 2008 Nonstatutory Stock Options
Nontransferability Awards Not Able Effectively Integrate Manage International Operations Such
Not Applicable Not Partner Unpartnered Programs Raise Additional Funds Curtail
Not Partner Unpartnered Programs Raise Additional Funds Further Not Successful Achieving Milestones Collaborations Advancing Programs Curtail
Not Successful Advancing Lead Programs Curtail Some Activities Not Voted Via Internet Telephone Fold Along Perforation
Notes Condensed Consolidated Financial Statements Basis Presentation Notice Adjustments
Notice Corporate Events Notice Withdrawal
Notices Now Therefore
Number 000-31161 Number Shares
Number Warrant Shares Obesity
Occurrence Other Event Board Determines Duly Approved Resolution Offering Periods
Officer Operation
Operations Might Interrupted Occurrence Natural Disaster Other Catastrophic Operations Risk Loss
Option Option Exercises Stock Vested 2007
Option Exercises Stock Vested 2008 Option Grants Last
Option Not Yet Delivered Share Certificates Refund Price Option Sar Grants Last
Option Term Options
Original Ortho-mcneil Collaboration
Ortho-mcneil Inc Ortho-mcneil Pharmaceutical Inc
Ortho-mcneil-janssen Collaboration Ortho-mcneil-janssen Pharmaceuticals Inc
Other Other Benefits Post-termination Compensation
Other Diabetes Programs Other Employee Benefits
Other Events Other Fees
Other Matters Other Obesity Programs
Other Plans Other Research Development Programs
Otices Outlook 2005
Outlook 2006 Outlook 2007
Outlook 2008 Outstanding Shares
Ovenants Elating Ollateral Ndebtedness Ividends Obligor Covenants Overning Urisdiction Ertain Aivers
Overview Overview Recent Developments
Parachute Payments Part
Part I-financial Information Participant
Participate New Partnerships Other Strategic Transactions Impact Liquidity Participating Executive Officers
Participation Participation 2009 Espp
Participation Employee Purchase Plan Participation Offering
Particular Covenants Events Default Patent Costs
Patent Means Patent Prosecution
Patient Disposition Payable Deerfield
Payment Payment Exercise Price
Payment Shares Exercise Stock Appreciation Right Such Shall Payment Warrant Exercise Price Cash Cashless Major
Payments Adjustments Payroll Deductions
Pct Peer Group
Per Protocol Efficacy Per Protocol Results
Performance Award Performance Awards
Performance Criteria Performance Graph
Performance Period Performance Share
Performance Unit Performance Unit Awards
Performance-based Cash Incentives Performance-based Restricted Stock Unit Awards
Perquisites Other Benefits Person
Phase Clinical Development Phase Program Overview
Plan Administrator Plan Match
Plan Sponsor Administrator Plan-year Goal Adjustment
Planned Improvements Post-termination Compensation
Potency Pre-approval Polices Procedures
Pre-approval Policies Procedures Preferred Stock
Preferred Stock Purchase Rights Premises
Presumptions Effect Certain Proceedings Previously Announced Efficacy Data
Primary Endpoint Analysis Principal Accountant Fees Services
Principal Accounting Fees Services Principles Consolidation
Prior Clinical Development Prior Plans
Pro Forma Information Sfas 123 2005 Pro Forma Information Sfas 123 Periods Prior 2006
Pro Rata Distributions Procedure Application Indemnification
Procedure Notification Defense Claim Product Candidates Subject Extensive Regulation Costly Time Consuming
Program Term Project Genesis
Promptly Signing Dating Returning Proxy Card Save Expense Properties
Property Equipment Property Purchase Price
Proposals Approve 2006 Long-term Incentive Plan Increase Number Proposals-the Board Directors Recommends Vote Nominees Listed Proposal
Proposed Annual Financial Statements Proposed Quarterly Financial Statements
Proposed Regulations Standards Proprietary Gpcr Technologies Programs
Provided Provided Further
Provided However Provisions Series Convertible Preferred Stock Prevent Make Difficult
Provisions Series Preferred Prevent Make Difficult Raise Funds Provisions Stock Appreciation Rights Need Not Same Respect
Proxy Solicited Behalf Board Directors 2005 Annual Meeting Proxy Solicited Behalf Board Directors 2007 Annual Meeting
Proxy Solicited Behalf Board Directors 2008 Annual Meeting Prudent Actions Plan Fiduciaries
Public Offering Common Stock Publications
Purchase Agreement Purchase Price
Purchase Price Shares Purchased Purchase Sale
Purchase Sale Common Stock Purchase Shares
Purpose Purpose Employee Purchase Plan
Purpose Plan Pursuant Securities Exchange Act 1934
Quality Life Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Data Questions Answers Proxy Material Voting
Rant Ecurity Nterest Ratification Appointment Ernst Young Llp
Ratification Independent Auditors Ratification Independent Auditors Proposal
Receive Information Plan Benefits Receiving Materials
Recently Issued Accounting Standards Recitals
Reclassifications Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock Warrants Reduced Amount
Registrants Telephone Number Including Area Code Registration Rights Agreement
Registration Transfers Registration Warrant
Release Releases
Rely Parties Conduct Clinical Trials Preclinical Studies Those Rely Parties Conduct Clinical Trials Those Not Successfully
Rely Third-party Manufacturers Such Parties Encounter Failures Difficulties Remainder Page Intentionally Left Blank
Remedies Indemnitee Replacement Compound
Replacement Warrant Report Board
Report Independent Registered Public Accounting Firm Report Independent Registered Public Accounting Firm Internal Control
Reports Representations Warranties
Representations Warranties Investor Repricing
Request Review Research Collaboration License Agreement
Research Development Costs Research Development Expenses
Research Development Programs Research Development Programs Early Stages Not Result Commencement
Research Term Extension Reservation Shares
Reservation Warrant Shares Responsibilities
Rest Page Intentionally Blank Restricted Stock
Restricted Stock Awards Restricted Stock Awards Performance
Restricted Stock Grant Agreement Restricted Stock Unit Awards
Restricted Stock Units Restrictions Transfer
Restructuring Charges Restructuring Plan
Results Operations Results Operations Financial Condition
Results Preclinical Studies Completed Clinical Trials Not Necessarily Results Preclinical Studies Initial Clinical Trials Not Necessarily
Retain Significant Commercial Rights Economic Value Drug Candidates Retain Significant Commercial Rights Economic Value Product Candidates
Revenue Recognition Revenues
Revenues Depend Actions Existing Potential Collaborators Revenues Least Short Term Depend Actions Collaborators Ability
Revenues Least Short-term Depend Actions Collaborators Ability Enter Rights Agreement Certain Provisions Charter Documents Delaware Law
Rights Stockholder Risk Assessment Management Insurance
Risk Factors Risks Relating Business
Risks Relating Intellectual Property Rules Governing Plan
Rules Procedures Rules Regulations
Safety Tolerability Profile Sales Stock Executive Officers Directors Adversely Affect Price
San Diego 92121 Sarbanes-oxley Act 2002
Schedule Schedule 14a
Scheduled Earnings Call Sec
Secondary Endpoint Analysis Secondary Endpoints
Sections 280g 4999 Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Amendment Securities Registered Pursuant Act
Security Agreement Security Ownership Certain Beneficial Owners Management
Security Ownership Certain Beneficial Owners Management Related Stockholder Selectivity
Self-assessment Seq
Setbacks Consolidation Pharmaceutical Biotechnology Industries Setbacks Consolidation Pharmaceutical Biotechnology Industries Collaborators Inability Obtain
Settlement Agreement Settlement Agreement Release
Settlement Effective Date Severability
Severance Benefit Plan Severance Period
Share-based Award Activity Share-based Compensation
Share-based Payment Shares Available Issuance
Short Term Short-term Investments Available-for-sale
Sight Draft Signature
Signature Page Follows Signatures
Significant Indebtedness Debt Service Obligations Result 100 Secured Significant Subsidiaries Arena Pharmaceuticals Inc
Solely Sources Availability Raw Materials Clinical Supplies
Sources Availability Raw Materials Intermediates Clinical Supplies Sources Uses Cash
Statement Erisa Rights Stock
Stock Appreciation Rights Stock Dividends Splits
Stock Options Stock Price Decline Significantly Based Results Timing Clinical
Stock Price Likely Volatile Investment Decline Value Stock-based Compensation
Stock-based Compensation Expense 2006 Thereafter Stock-based Incentives
Stockholder Communications Board Directors Stockholder Director Recommendations
Stockholder Proposals 2006 Annual Meeting Stockholder Proposals 2007 Annual Meeting
Stockholder Proposals 2008 Annual Meeting Stockholder Proposals 2009 Annual Meeting
Stockholder Record Stockholder Record Shares Registered Name
Stockholders Equity Stockholders Rights Plan
Strategy Subject Adjustment Provided 122 Total 6000000 Shares Shall
Submission Matters Vote Security Holders Submissions Include Representation Nominating Stockholder Beneficial Record Owner
Submissions Matters Vote Security Holders Subscription Agreement
Subsequent Event Subsequent Events
Subsidiary Substantial Number Shares Common Stock Eligible Future Sale
Substitute Awards Success Dependent Intellectual Property Rights Held Parties Interest
Summary Compensation Table Summary Revenues Expenses
Survival Table Above Not List Research Programs
Table Contents Taigen Biotechnology Ltd
Target Award Salary Tax Considerations
Tax Deduction Tax Fees
Tax Strategy Taxes Duties Fees
Technologies Rely Not Result Discovery Development Commercially Viable Telephone
Term Term Expiration Date
Term Option Term Plan
Termination Termination Benefits
Termination Employment Termination Material Definitive Agreement
Termination Protection Termination Protection Agreements
Termination Service Terms Conditions
Terms Conditions Awards Terms Conditions Options
Thank Voting Third-party Manufacturer Encounter Failures Difficulties Delay Clinical Development
Third-party Manufacturer Encounter Manufacturing Failure Delay Clinical Development Threshold
Title Survey Review Transfer Notice
Transfer Registration Transferability
Transferability Awards Treasury Stock
Understand Agree Completely Terms Set Forth Understand Subscription Agreement Shall Remain Effect Throughout Successive
United States Unless
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Upcoming Corporate Presentations Updated 2008 Financial Guidance
Updated Financial Guidance 2006 Updated Financial Guidance 2007
Valuation Series Convertible Preferred Stock Related Warrants Unit Valuation Share-based Compensation Sfas 123r
Value Received Very Successful
Vest Date Vested Shares Vesting
Vesting Period Shall Mean Time Specified Committee Restrictions Vitro
Vivo Vote Telephone Internet Available
Vote Votes Counted Votes Nominees Receive Elected Directors
Votes Ratification Ernst Young Llp Independent Auditors Ending Votes Received Approve Amendment 2001 Arena Employee Stock
Votes Received Approve Amendment Fifth Amended Restated Certificate Votes Received Approve Arena Pharmaceuticals Inc 2006 Long-term
Voting Mail Complete Sections Sides Card Wall Street Journal
Warrant Warrant Agent
Warrant Liability Warrant Register
Warrant Shares Warrants
Weight Management What Proxy Card
What Voting Whereas
Win-win Solution Withdrawal
Withholding Witness Whereof
Xhibit Ndex 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki